Tirzepatide 30mg

Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide engineered to activate two metabolic receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is the first dual incretin agonist to demonstrate clinical superiority over selective GLP-1 receptor agonism for weight reduction, and it has become the reference compound for researchers investigating combined incretin pathway signaling.

The design logic is deliberate. GIP receptor activation is studied for its role in insulin sensitivity and adipocyte biology, while GLP-1 receptor activation drives appetite suppression and glucose-dependent insulin release. Tirzepatide binds both receptors with high affinity, though its activity at the GLP-1 receptor is lower than that of native GLP-1, and it behaves as a biased agonist at GLP-1R—preferentially signaling through adenylyl cyclase rather than β-arrestin recruitment. A C20 fatty diacid moiety enables albumin binding and extends the half-life to support once-weekly dosing in research protocols.

This research-grade Tirzepatide is supplied as a sterile, lyophilized powder, independently verified by HPLC-UV (≥98% purity) and LC-MS identity confirmation, with a batch-specific Certificate of Analysis for full traceability.

Proposed mechanisms of interest in published literature:

Dual GIPR/GLP-1R agonism: Tirzepatide selectively binds and activates both the GIP and GLP-1 receptors—the targets for native GIP and GLP-1—enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner. Both receptor populations are present on pancreatic α and β cells, brain, heart, vasculature, immune cells, gut, and kidney, with GIP receptors additionally expressed on adipocytes.

Biased signaling at GLP-1R: Unlike native GLP-1, Tirzepatide preferentially activates adenylyl cyclase over β-arrestin recruitment at the GLP-1 receptor—a signaling bias that researchers study for its contribution to the compound’s efficacy and tolerability profile.

Greater incretin receptor engagement: Molecular dynamics studies indicate that conserved residues contribute similarly to binding at both GLP-1R and GIPR, while mutations in non-conserved residues affect binding affinity differentially—with C-terminal mutations weakening GLP-1R affinity more than GIPR affinity.

Metabolic and body composition effects (preclinical): In diet-induced obese mouse models, Tirzepatide (10 nM/kg, subcutaneous) reduced body weight and food consumption, and lowered glucose, insulin, leptin, and C-peptide levels. Separate studies have investigated neuroprotective effects in high-glucose neuroblastoma cell models and in diabetic rats, where it improved spatial learning and memory impairment.

Clinical superiority over GLP-1 monotherapy: In the SURMOUNT-5 phase 3b trial, Tirzepatide produced a least-squares mean weight change of −20.2% at week 72 versus −13.7% with semaglutide, with significantly greater reductions in waist circumference (−18.4 cm vs −13.0 cm) and a higher proportion of participants achieving ≥10%, ≥15%, ≥20%, and ≥25% weight reduction.

Clinical research context (Phase 3 data):

Tirzepatide has one of the most extensive clinical datasets in the incretin class.

SURMOUNT-J (obesity, 72 weeks, n=225): Estimated treatment differences relative to placebo in body weight change were −16.1% (10 mg) and −21.1% (15 mg). At week 72, 94% (10 mg) and 96% (15 mg) of participants achieved ≥5% bodyweight reduction, versus 20% with placebo.

SURMOUNT-5 (head-to-head vs semaglutide, 72 weeks, n=751): Tirzepatide was superior to semaglutide for reduction in body weight (−20.2% vs −13.7%) and waist circumference (−18.4 cm vs −13.0 cm).

Tolerability: Gastrointestinal events were the most common adverse effects in both treatment groups, generally mild to moderate in severity and occurring primarily during dose escalation. Discontinuations due to adverse events were infrequent in the SURMOUNT-J trial (placebo: 4%; Tirzepatide 10 mg: 1%; Tirzepatide 15 mg: 0%).

Product specifications:

Compound: Tirzepatide (LY3298176)

CAS Number: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: 4813.45 g/mol

Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-[C20 diacid-γ-Glu-(AEEA)2-Lys]-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-NH₂

Peptide Length: 39 amino acids, with non-coded residues (Aib) and a C-terminal amide

Appearance: White to off-white lyophilized powder

Form: Lyophilized powder

Purity: ≥98% by HPLC-UV (batch-specific COA; representative research lots test 99.0%–99.8%)

Identity Confirmation: LC-MS (mass spectrometry)

Solubility: Soluble in bacteriostatic water and sterile saline

Storage (lyophilized): −20°C, desiccated, protected from light

Handling & reconstitution (research context):

Reconstitute with bacteriostatic water using aseptic technique. Inject the water slowly down the inner glass wall of the vial—do not spray directly onto the powder—then gently swirl or roll the vial. Do not shake or vortex; the 39-amino-acid sequence and its lipid modification are sensitive to aggressive agitation.

Once reconstituted, store refrigerated at 2–8°C and use within 2–4 weeks. Do not freeze reconstituted peptide. Aliquot into single-use volumes where protocol permits to avoid repeated freeze–thaw cycles.

Quick answers

Who needs the 30mg strength?

Established protocols at the upper 7.5-10mg weekly bands - the vial sized for experienced titrators holding a step for a full month without mid-run reorders. If you are still easing in from 10mg, this vial waits; ladders reward patience, and 20mg is where the middle months live.

Does upper-band dosing change side-effect rules?

The rules intensify, not change: protein-first meals, fat last, alcohol optional at best, and a fresh tolerance check at every step-up week. Nausea that repeats at the same step is a hold signal, not a fight-through signal.

What pairs with a high-tier tirzepatide run?

Nothing stimulating - the fat burners shelf covers adjuncts, but high-band tirzepatide rarely needs company. It needs training, protein, and the mid-run markers listed in the panel guide.